190 related articles for article (PubMed ID: 30472259)
1. Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer.
Karachaliou N; Bracht JWP; Fernandez Bruno M; Drozdowskyj A; Gimenez Capitan A; Moran T; Carcereny E; Cobo M; Domine M; Chaib I; Ramirez JL; Camps C; Provencio M; Vergnenegre A; Lopez-Vivanco G; Majem M; Massuti B; Rosell R
J Thorac Oncol; 2019 Feb; 14(2):304-310. PubMed ID: 30472259
[TBL] [Abstract][Full Text] [Related]
2. Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies.
Moran T; Wei J; Cobo M; Qian X; Domine M; Zou Z; Bover I; Wang L; Provencio M; Yu L; Chaib I; You C; Massuti B; Song Y; Vergnenegre A; Lu H; Lopez-Vivanco G; Hu W; Robinet G; Yan J; Insa A; Xu X; Majem M; Chen X; de Las Peñas R; Karachaliou N; Sala MA; Wu Q; Isla D; Zhou Y; Baize N; Zhang F; Garde J; Germonpre P; Rauh S; ALHusaini H; Sanchez-Ronco M; Drozdowskyj A; Sanchez JJ; Camps C; Liu B; Rosell R; ; Colinet B; De Grève J; Germonpré P; Chen H; Chen X; Du J; Gao Y; Hu J; Hu W; Kong W; Li L; Li R; Li X; Liu B; Liu J; Lu H; Qian X; Ren W; Song Y; Wang L; Wei J; Wen L; Wu Q; Xiao X; Xu X; Yan J; Yang J; Yang M; Yang Y; Yin J; You C; Yu L; Yue X; Zhang F; Zhang J; Zhou Y; Zhu L; Zou Z; Baize N; Bombaron P; Chouaid C; Dansin E; Fournel P; Fraboulet G; Gervais R; Hominal S; Kahlout S; Lecaer H; Lena H; LeTreut J; Locher C; Molinier O; Monnet I; Oliviero G; Robinet G; Schoot R; Thomas P; Vergnènegre A; Berchem G; Rauh S; Al Husaini H; Aparisi F; Arriola E; Ballesteros I; Barneto I; Bernabé R; Blasco A; Bosch-Barrera J; Bover I; Calvo de Juan V; Camps C; Carcereny E; Catot S; Cobo M; De Las Peñas R; Dómine M; Felip E; García-Campelo MR; García-Girón C; García-Gómez R; Garcia-Sevila R; Garde J; Gasco A; Gil J; González-Larriba JL; Hernando-Polo S; Jantus E; Insa A; Isla D; Jiménez B; Lianes P; López-López R; López-Martín A; López-Vivanco G; Macias JA; Majem M; Marti-Ciriquian JL; Massuti B; Montoyo R; Morales-Espinosa D; Morán T; Moreno MA; Pallares C; Parera M; Pérez-Carrión R; Porta R; Provencio M; Reguart N; Rosell R; Rosillo F; Sala MA; Sanchez JM; Sullivan I; Terrasa J; Trigo JM; Valdivia J; Viñolas N; Viteri S; Botia-Castillo M; Mate JL; Perez-Cano M; Ramirez JL; Sanchez-Rodriguez B; Taron M; Tierno-Garcia M; Mijangos E; Ocaña J; Pereira E; Shao J; Sun X; O'Brate R
Ann Oncol; 2014 Nov; 25(11):2147-2155. PubMed ID: 25164908
[TBL] [Abstract][Full Text] [Related]
3. [Chinese multicenter randomized trial of customized chemotherapy based on BRCA1 (breast cancer susceptibility gene 1)-RAP80 (receptor-associated protein 80) mRNA expression in advanced non-small cell lung cancer (NSCLC) patients].
Wei J; Qian XP; Zou ZY; Wang LF; Yu LX; You CW; Song Y; Lu HY; Hu WJ; Yan J; Xu XX; Chen XF; Li XY; Wu QF; Zhou Y; Zhang FL; Liu BR
Zhonghua Zhong Liu Za Zhi; 2016 Nov; 38(11):868-873. PubMed ID: 27998448
[No Abstract] [Full Text] [Related]
4. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
Booton R; Ward T; Ashcroft L; Morris J; Heighway J; Thatcher N
J Thorac Oncol; 2007 Oct; 2(10):902-6. PubMed ID: 17909351
[TBL] [Abstract][Full Text] [Related]
5. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression.
Rosell R; Perez-Roca L; Sanchez JJ; Cobo M; Moran T; Chaib I; Provencio M; Domine M; Sala MA; Jimenez U; Diz P; Barneto I; Macias JA; de Las Peñas R; Catot S; Isla D; Sanchez JM; Ibeas R; Lopez-Vivanco G; Oramas J; Mendez P; Reguart N; Blanco R; Taron M
PLoS One; 2009; 4(5):e5133. PubMed ID: 19415121
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J
Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Impact of DNA Repair Protein Expression in Non-Small Cell Lung Cancers Treated with Platinum-Based Chemotherapy and Subsequent Curative Lung Resection.
Shin J; Lee KS; Yoh KA; Cho HJ; Choi MK; Kim SH; Kim YJ; Chung JH; Cho S; Kim K; Jheon S; Yoon HI; Lee JH; Lee CT; Lee JS
Oncology; 2018; 95(1):20-30. PubMed ID: 29694959
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.
Kubota K; Sakai H; Katakami N; Nishio M; Inoue A; Okamoto H; Isobe H; Kunitoh H; Takiguchi Y; Kobayashi K; Nakamura Y; Ohmatsu H; Sugawara S; Minato K; Fukuda M; Yokoyama A; Takeuchi M; Michimae H; Gemma A; Kudoh S;
Ann Oncol; 2015 Jul; 26(7):1401-8. PubMed ID: 25908605
[TBL] [Abstract][Full Text] [Related]
9. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
Golan T; O'Kane GM; Denroche RE; Raitses-Gurevich M; Grant RC; Holter S; Wang Y; Zhang A; Jang GH; Stossel C; Atias D; Halperin S; Berger R; Glick Y; Park JP; Cuggia A; Williamson L; Wong HL; Schaeffer DF; Renouf DJ; Borgida A; Dodd A; Wilson JM; Fischer SE; Notta F; Knox JJ; Zogopoulos G; Gallinger S
Gastroenterology; 2021 May; 160(6):2119-2132.e9. PubMed ID: 33524400
[TBL] [Abstract][Full Text] [Related]
10. The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy.
Bonanno L; Costa C; Majem M; Sanchez JJ; Gimenez-Capitan A; Rodriguez I; Vergnenegre A; Massuti B; Favaretto A; Rugge M; Pallares C; Taron M; Rosell R
Oncotarget; 2013 Oct; 4(10):1572-81. PubMed ID: 24197907
[TBL] [Abstract][Full Text] [Related]
11. ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer.
Papadaki C; Sfakianaki M; Ioannidis G; Lagoudaki E; Trypaki M; Tryfonidis K; Mavroudis D; Stathopoulos E; Georgoulias V; Souglakos J
J Thorac Oncol; 2012 Apr; 7(4):663-71. PubMed ID: 22425915
[TBL] [Abstract][Full Text] [Related]
12. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.
Isla D; Sarries C; Rosell R; Alonso G; Domine M; Taron M; Lopez-Vivanco G; Camps C; Botia M; Nuñez L; Sanchez-Ronco M; Sanchez JJ; Lopez-Brea M; Barneto I; Paredes A; Medina B; Artal A; Lianes P
Ann Oncol; 2004 Aug; 15(8):1194-203. PubMed ID: 15277258
[TBL] [Abstract][Full Text] [Related]
13. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer.
Fujii T; Toyooka S; Ichimura K; Fujiwara Y; Hotta K; Soh J; Suehisa H; Kobayashi N; Aoe M; Yoshino T; Kiura K; Date H
Lung Cancer; 2008 Mar; 59(3):377-84. PubMed ID: 17905465
[TBL] [Abstract][Full Text] [Related]
14. Effect of RIF1 on response of non-small-cell lung cancer patients to platinum-based chemotherapy by regulating MYC signaling pathway.
Mei Y; Liu YB; Hu DL; Zhou HH
Int J Biol Sci; 2018; 14(13):1859-1872. PubMed ID: 30443189
[TBL] [Abstract][Full Text] [Related]
15. Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization.
Kadouri L; Rottenberg Y; Zick A; Hamburger T; Lipson D; Peretz T; Nechushtan H
Lung Cancer; 2019 Nov; 137():48-51. PubMed ID: 31542568
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of ataxia-telangiectasia mutated, DNA-dependent protein kinase catalytic subunit, and Ku heterodimeric regulatory complex 86-kD subunit expression in patients with nonsmall cell lung cancer.
Xing J; Wu X; Vaporciyan AA; Spitz MR; Gu J
Cancer; 2008 Jun; 112(12):2756-64. PubMed ID: 18457328
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract][Full Text] [Related]
19. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
[TBL] [Abstract][Full Text] [Related]
20. Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival.
Li J; Li ZN; Du YJ; Li XQ; Bao QL; Chen P
Clin Lung Cancer; 2009 Nov; 10(6):414-21. PubMed ID: 19900859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
